NIMBEX LIQUID

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

CISATRACURIUM (CISATRACURIUM BESYLATE)

제공처:

ABBVIE CORPORATION

ATC 코드:

M03AC11

INN (International Name):

CISATRACURIUM

복용량:

2MG

약제 형태:

LIQUID

구성:

CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG

관리 경로:

INTRAVENOUS

패키지 단위:

10 ML(VIAL)

처방전 유형:

Prescription

치료 영역:

NEUROMUSCULAR BLOCKING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0133260001; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2016-06-07

제품 특성 요약

_NIMBEX_
_®_
_ Product Monograph _
_Page 1 of 34 _
PRODUCT MONOGRAPH
PR
NIMBEX
®
cisatracurium besylate injection
solution for injection (2 mg/mL)
Non-depolarizing Skeletal Neuromuscular Blocking Agent
THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED
PROFESSIONALS FAMILIAR WITH
ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.
NOTE: NIMBEX
®
is a trademark of the Glaxo group of companies, AbbVie Corporation
licensed use.
_ _
Date of Preparation:
November 1, 2012
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Qc H4S 1Z1
Submission Control No: 158348
_NIMBEX_
_®_
_ Product Monograph _
_Page 2 of 34 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND ADMINISTRATION
..............................................................................12
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................26
SPECIAL HANDLING INSTRUCTIONS
.......................................................................26
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................